Androgen receptor (AR) is the major therapeutic target in aggressive prostate cancer. However, targeting AR alone can result in drug resistance and disease recurrence. Therefore, simultaneous targeting of multiple pathways could in principle be an effective approach to treating prostate cancer. Here we provide proof-of-concept that a small-molecule inhibitor of nuclear β-catenin activity (called C3) can inhibit both the AR and β-catenin-signaling pathways that are often misregulated in prostate cancer. Treatment with C3 ablated prostate cancer cell growth by disruption of both β-catenin/T-cell factor and β-catenin/AR protein interaction, reflecting the fact that T-cell factor and AR have overlapping binding sites on β-catenin. Given that AR interacts with, and is transcriptionally regulated by β-catenin, C3 treatment also resulted in decreased occupancy of β-catenin on the AR promoter and diminished AR and AR/β-catenin target gene expression. Interestingly, C3 treatment resulted in decreased AR binding to target genes accompanied by decreased recruitment of an AR and β-catenin cofactor, coactivator-associated arginine methyltransferase 1 (CARM1), providing insight into the unrecognized function of β-catenin in prostate cancer. Importantly, C3 inhibited tumor growth in an in vivo xenograft model and blocked renewal of bicalutamide-resistant sphere-forming cells, indicating the therapeutic potential of this approach. P rostate cancer is the most common form of cancer in males and is currently treated with androgen deprivation therapy. Although this results in tumor regression, aggressive disease typically recurs, making the treatment of what is then called castrationresistant prostate cancer (CRPC) the major challenge in the field. Androgen receptor (AR) up-regulation is the major determinate in CRPC (1), but conventional anti-androgen drugs fail to block AR activity in CRPCs where they can gain partial AR agonist properties (1) . Promising drugs have been reported (2, 3) , but they extend life by only 4-5 mo (4), hinting that targeting AR activity might not be enough to inhibit tumor growth, given that increased crosstalk between distinct signaling pathways causes activation of AR regulatory networks in advanced prostate cancer (5) . Therefore, development of drugs that target multiple pathways or can be used sequentially will further improve life expectancy.
Growing evidence indicates that the canonical Wnt/β-catenin pathway plays an important role in prostate tumorigenesis (6) . Recent studies reveal that Wnt signaling is a significantly mutated pathway in lethal CRPC (7) . Additionally, Wnt16B promotes resistant disease, underscoring the importance of targeting the Wnt/β-catenin pathway in advanced disease (8) . Synergy between AR and β-catenin pathways has been well documented. AR binds β-catenin directly to stimulate AR-mediated gene transcription (9) , and importantly, the AR gene itself is a transcriptional target of β-catenin (10). Furthermore, enhanced crosstalk between AR and β-catenin has been observed in in vivo models of CRPC (11) . Therefore, hypothetically, inhibitors of nuclear β-catenin would modulate AR and its target genes, including the direct targets of β-catenin such as C-MYC, which acts as an oncogene in prostate cancer (12) .
Recent studies have identified a small subpopulation of cancer cells-termed "cancer stem cells" (CSCs) or "tumor-initiating cells," based on their ability to self-renew-that play a critical role in both initiation and maintenance of tumors (13) . These cells are resistant to conventional chemotherapy and radiation (14) , and, in prostate cancer, CSCs may survive after androgen ablation therapy, causing CRPC (15) . Wnt/β-catenin signaling is highly active in CSCs (16) (17) (18) , providing an additional rationale to target the Wnt/β-catenin pathway in prostate cancer.
In this study, we used a recently identified small-molecule inhibitor of nuclear β-catenin function, called "inhibitor of β-catenin responsive transcription" (iCRT) (19) , to test the hypothesis that inhibition of nuclear β-catenin would repress prostate cancer growth by disrupting both AR and Wnt/β-catenin signaling. The use of inhibitors that specifically target the nuclear function of β-catenin may avoid disruption of cell-cell adherens junctions, which has been implicated in promoting epithelialmesenchymal transition and metastasis. We tested the three lead compounds isolated in the previous study, iCRT-3, -5, and -14 (19) , for inhibition of prostate cancer cell growth and selected iCRT3 (referred to as C3 from here on) for further analysis based on its high potency. We found that C3 interferes with two different protein-protein interactions in prostate cancer cells, T-cell factor (TCF)/β-catenin and AR/β-catenin. In addition, C3 inhibited both in vitro and in vivo proliferation of the LNCaPabl, androgen-receptor-sensitive but androgen-ligand-insensitive cell line, which serves as a model of CRPC (20) . Importantly, C3 inhibited self-renewal of prostate cancer cells that express higher levels of stem-cell markers, suggesting that inhibition of nuclear β-catenin function may be an important therapeutic approach to advanced prostate cancer treatment.
Results

C3
Affects AR and β-Catenin Signaling by Inhibition of ProteinProtein Interaction. Given that AR interacts with, and is transcriptionally regulated by, β-catenin, we reasoned that inhibition of nuclear β-catenin could interfere with both AR and β-catenin signaling. C3 (Fig. 1A ) was shown to specifically inhibit Wnt/ β-catenin-induced transcription by interfering with the interaction between β-catenin and TCF-4 (19) . Because AR and TCF-4 have overlapping interaction domains with β-catenin (9, 21), we hypothesized that C3 may also inhibit AR and β-catenin interaction. In support of this idea, C3 robustly inhibited β-catenin/TCF-4 as well as β-catenin/AR interactions in LNCaP cells (Fig. 1B) .
We examined the levels of nuclear (transcriptionally active) β-catenin in androgen-dependent LNCaP cells, an androgenindependent LNCaP cell derivative called LNCaP-abl (20) , and androgen-dependent VCaP cells, which have amplified AR (22) . β-Catenin was abundantly expressed in the nucleus of all three cell lines, indicating that they may be susceptible to β-catenin inhibition ( Fig. 1C and Fig. S1A ). Importantly, C3 did not disrupt localization of junctional β-catenin at the cell membrane (Fig.  S1B) , the loss of which is implicated in tumor metastasis. This article is a PNAS Direct Submission. 1 To whom correspondence may be addressed. E-mail: susan.logan@nyumc.org or ramanuj.dasgupta@nyumc.org.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. 1073/pnas.1218168110/-/DCSupplemental.
As AR is transcriptionally regulated by β-catenin through TCF/lymphoid enhancer factor (LEF)-binding sites on the AR promoter, we reasoned that loss of TCF/β-catenin interaction would diminish AR mRNA levels in C3-treated cells. To test if transcription of AR is directly targeted by C3, nascent AR mRNA levels were analyzed in LNCaP cells using primers flanking exon/intron junctions. Indeed, C3 treatment decreased nascent AR mRNA levels (Fig. 1D) , consistent with the decreased occupancy of β-catenin on TCF/LEF-binding sites within the AR promoter shown by chromatin immunoprecipitation (ChIP) (Fig. 1E) . Depletion of β-catenin revealed that cells retaining strong β-catenin levels due to incomplete knockdown (Fig. 1F, arrow) clearly have higher levels of AR than adjacent cells with lower levels of β-catenin (Fig. 1F, arrowheads) , indicating that the cell-specific expression of AR is regulated by β-catenin.
We next tested the effect of C3 on transcriptional activities of AR and β-catenin. C3 dramatically reduced expression of both AR and Wnt/β-catenin reporter genes (Fig. S1C) , and the overexpression of AR cDNA diminished the inhibitory effect of C3 on AR reporter activity (Fig. S1D ), suggesting that C3 may directly influence AR activity. Dose-responsive inhibition of C3 on AR and Wnt/β-catenin transcriptional activities revealed that C3 inhibits the Wnt/β-catenin reporter with an IC 50 of 0.14 μM in LNCaP, 0.89 μM in abl, and 0.97 μM in VCaP cells (Fig. 1G) . The somewhat higher IC 50 in abl cells likely reflects the increased activity of nuclear β-catenin as seen in other androgen-independent cell lines and in a CRPC model (11, 23) . Also, the higher IC 50 in VCaP cells is consistent with the previous report showing ETS-related gene (ERG)-induced Wnt signaling (24) . The IC 50 needed to inhibit the AR reporter was comparable between LNCaP and abl cells (Fig.  1G, 1 .44 and 1.61 μM), but higher in VCaP cells (6.51 μM), reflecting the amplification of AR in VCaP cells (22) .
AR ligand competition assays were conducted to test if C3 modulates AR activity by affecting ligand binding. Samples incubated with C3 showed that C3 does not affect ligand binding (Fig. S1E) . Examination of AR coactivator recruitment showed that C3 did not induce recruitment of the FxxLF coactivator peptide to the AR ligand-binding domain (LBD), whereas dihydrotestosterone (DHT) and higher concentrations of the AR antagonist bicalutamide (BIC) induced dose-dependent interaction of the peptide and AR-LBD (Fig. S1F ).
C3 Inhibits AR and Wnt/β-Catenin Target Gene Expression. Next, we evaluated the impact of C3 on endogenous AR and Wnt/β-catenin target genes. LNCaP and VCaP cells were treated with vehicle or R1881 at the growth-promoting concentration of 0.1 nM in the presence or absence of C3, and abl cells, which grow in the absence of androgens, were treated only with C3. AR mRNA was quantified along with the well-characterized AR target genes, prostate-specific antigen (PSA) and NK3 homeobox 1 (NKX3.1). In addition, we examined cell-division cycle protein 20 (CDC20), cyclin-dependent kinase 1 (CDK1), and ubiquitin-conjugating enzyme E2C (UBE2C), M-phase cell-cycle regulatory genes that are AR targets in abl cells (25) . Levels of the Wnt/β-catenin target gene, C-MYC, were also examined. C3 treatment decreased transcription of AR mRNA and AR and β-catenin target genes in both LNCaP and abl cells ( Fig. 2 A and  B) . This inhibitory effect was observed as early as 4 h after treatment in some of the target genes ( Fig. S2A ) and persisted up to 48 h after treatment (Fig. S2B) . Expression of control genes, E-cadherin, and the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) remained unaffected ( Fig. 2 A  and B) . We also tested transcription of a gene, mannosyl-oligosaccharide 1,2-alpha-mannosidase IA (MAN1A1), reported to be repressed by AR (26) . The results shown in Fig. 2 A and B indicate that MAN1A is derepressed in response to C3 treatment in both LNCaP and abl cells, suggesting that there is altered transcription of genes both positively and negatively regulated by AR in response to C3 treatment. Decreased protein levels of target genes in C3-treated LNCaP, abl, and VCaP cells were also observed, consistent with decreased mRNA levels ( Fig. 2C and Fig.  S2D ). Treatment of VCaP cells with C3 also inhibited mRNA expression of target genes in the presence of R1881, with the exception of NKX3.1 (Fig. S2C ). There are some differences in target gene expression upon C3 treatment between the LNCaP and VCaP cells ( Fig. 2A versus Fig. S2C ), reflecting the possibility that VCaP cells may use a different mechanism to regulate the Wnt pathway than LNCaP cells as suggested by a study showing that the TMPRSS2-ERG fusion gene in VCaP cells upregulates Wnt pathway components, including the receptor frizzled-4 (24) . Next, we tested if the expression of AR and Wnt/ β-catenin target genes is similarly affected by β-catenin depletion. RNAi-mediated depletion of β-catenin in LNCaP and abl cells resulted in down-regulation of AR levels, as well as AR and Wnt/β-catenin target gene expression, in a manner similar to that observed upon C3 treatment (Fig. 2 D and E) . Notably, in abl cells, although the M-phase cell-cycle regulatory genes (CDC20, CDK1, and UBE2C) were uniformly decreased in β-catenindepleted cells, PSA and NKX3.1 expression was not affected, indicating that AR is rate-limiting for expression of these cellcycle genes in abl cells as previously reported (25) .
As an independent assessment for the effect of C3 on the transcription of Wnt/β-catenin and AR target genes, we performed global transcriptome sequence profiling on RNA isolated from abl cells treated with either C3 compared with vehicle or small interfering RNAs (si-RNAs) directed against β-catenin (si-β-catenin) or AR (si-AR) compared with scrambled siRNA control ( Fig. S3) . As depicted by gene set enrichment analysis (GSEA), C3 and si-β-catenin treatments show comparable, overlapping enrichments of a known set of 124 β-catenin targets (Fig. S3A) (www. stanford.edu/group/nusselab/cgi-bin/wnt/target_genes). Although si-AR also shows enrichment, the si-AR partially intersects with the control enrichment area, suggesting that the effect of AR knockdown on β-catenin targets is not as significant as C3 and si-β-catenin. Additionally, clustering analysis using known β-catenin target genes confirmed that treatment with si-β-catenin, C3, and si-AR resulted in similar genes being differentially expressed, with the greatest overlap in the si-β-catenin and C3 treatments (Fig. S3A′) . GSEA analysis of a set of 179 previously annotated AR target genes (25) revealed that although there is a clear separation between the GSEA graphs of si-AR and si-β-catenin compared with controls, it is not as strong as for the β-catenin target gene set, suggesting that although some target genes may be commonly regulated by β-catenin and AR, there must be distinct sets of AR-specific target genes that are independent of β-catenin regulation (Fig. S3B) . Consistent with GSEA, cluster analysis indicates that there were some AR target genes similarly affected by si-β-catenin, C3, and AR siRNA and others affected by si-AR and either C3 or si-β-catenin (Fig. S3B′) . Given that off-target effects (OTEs) are a critical factor to consider for small-molecule inhibitors, we reanalyzed the top 1,000 genes down-regulated in cells treated with si-β-catenin and compared the effect on their expression by C3 and si-AR treatment (a description of the method of analysis is in the legend for Fig. S3  C and D) . Fig. S3D shows a fairly similar range of overlap between C3 and si-β-catenin (67-58%) and si-AR and si-β-catenin (74-48%). At face value, this indicates that the upper limit of OTEs for C3 is 33-42%. However, some OTEs may result from intrinsic experimental error, such as biological variability and incomplete knockout of β-catenin, as observed in Fig. 2D , and, given that some of the known Wnt/β-catenin targets such as frizzled-7, vascular endothelial growth factor (VEGF), and fibroblast growth factor (FGF) were found among the genes that appear to be specifically modulated by C3, but not by si-β-catenin. Taken together, the GSEA and clustering analysis strongly suggest that C3 targets a similar set of β-catenin target genes compared with si-β-catenin.
C3 Blocks Proliferation of Prostate Cancer Cells by Inducing Cell
Death. To test if C3 inhibits prostate cell growth, LNCaP, abl, and VCaP cells were treated with varying concentrations of C3 or vehicle. Treatment with 20 μM C3 completely abolished growth of LNCaP, abl (Fig. 3A) , and VCaP cells (Fig. S4A) . Whereas a 24-h treatment of C3 induced growth arrest of the cells in G0/G1 (Fig.  3A, Lower) , a 72-h treatment induced apoptosis shown by increased levels of poly ADP-ribose polymerase (PARP) cleavage (Fig. 3B) . To determine if C3 was generally toxic, as opposed to inhibiting specific pathways in individual cell types, we examined the effect of C3 on HEK 293 cells, which require Wnt ligand for activation of the pathway (27) . Although higher levels of C3 modestly slow cell growth in HEK 293 cells (Fig. 3C) , apoptosis was not induced (Fig.  3D) . β-Catenin depletion significantly reduced growth of LNCaP, abl, and VCaP cells ( Fig. 3E; Figs. S4B and S5) , indicating that the proliferation of prostate cancer cells is dependent on β-catenin.
C3 Inhibits AR and β-Catenin Occupancy on Target Genes. Because β-catenin can act as an AR coactivator (28, 29) and we found that C3 inhibits AR/β-catenin protein interaction (Fig. 1) , we reasoned that C3 might affect AR recruitment to target genes. To test this hypothesis, we examined AR occupancy in the presence and absence of C3 via ChIP. To circumvent the reduced levels of total AR observed in C3-treated cells in the presence of low (0.1 nM) androgen concentration (Fig. 2) , we treated cells with 100 nM DHT, which stabilized AR protein and diminished the inhibitory effect of C3 on total AR levels (Fig. 4A) . The inhibitory effect of C3 on transcription of AR and Wnt/β-catenin target genes was sustained when C3 was treated with 100 nM DHT (Fig.  4B) . A comparison of AR and β-catenin recruitment to the PSA and UBE2C enhancers showed that both proteins were recruited in response to DHT treatment but cells treated with C3 and DHT exhibited decreased recruitment of both proteins (Fig. 4 C and  D) . ChIP results on the C-MYC promoter showed that whereas DHT treatment increased β-catenin occupancy, C3 decreased this recruitment to a great extent (Fig. 4D) . Consistent with a previous report (30) , AR was also recruited to C-MYC promoter in response to DHT but the level of recruitment was modest and was not affected by C3 treatment, suggesting that β-catenin does not mediate AR binding to the C-MYC promoter (Fig. 4C) .
Given the dynamic nature of AR and cofactor interaction with chromatin (31) , and the role of β-catenin as a scaffolding protein (32), we reasoned that C3 might impact β-catenin-mediated interaction of AR with the chromatin-remodeling or -modifying machinery that could impact AR occupancy. To test this idea, we determined if C3 affected occupancy of commonly acknowledged coactivators of AR and β-catenin including p300, glutamate receptor-interacting protein 1 (GRIP1), coactivator-associated arginine methyltransferase 1 (CARM1), and BRG1 on AR target genes. These coactivators were recruited to both AR and β-catenin/ TCF-binding sites (33) (34) (35) (36) , and the physical interaction between some of the coactivators and AR or β-catenin has been shown (9, 28, 37, 38) . GRIP1 and p300 are histone acetyltransferases (39, 40) , and BRG1 is a core component of the SWI/SNF chromatinremodeling complex (41) . CARM1 is a histone methyltransferase that methylates arginine residues such as arginine 17 of histone H3 (H3R17), which is associated with transcriptional activation (42) . The protein levels of these coactivators were not affected by C3 treatment (Fig. S6A) . When we tested the occupancy of p300, GRIP1, CARM1, and BRG1 on PSA enhancer in the absence and presence of C3, no differences were observed (Fig. S6B) . However, similar to the AR and β-catenin ChIP results (Fig. 4 C and D) , C3 inhibited CARM1 occupancy on PSA and UBE2C enhancers (Fig.  4E) accompanied by decreased levels of dimethyl-H3R17 (Fig. 4F) . These results suggest that β-catenin might mediate CARM1 recruitment to AR and that the reduced levels of CARM1 and dimethyl-H3R17 in PSA and UBE2C enhancers in the presence of C3 impaired the open chromatin structure of androgen response elements (AREs) required for AR binding. Supporting this idea, CARM1 inhibitor treatment recapitulated the inhibitory effect of C3 on PSA and UBE2C (but not C-MYC) transcription as well as AR recruitment on PSA and UBE2C (Fig. S7) .
C3 Inhibits Self-Renewal Ability of Prostate Cancer Cells That Express
Higher Levels of Stem Cell Markers. The in vitro sphere-forming assay has been widely used to study prostate stem/cancer stem-cell biology (43) . Human prostate sphere-forming cells have also been demonstrated to self-renew and regenerate prostate tissue in vivo (44) . When we generated spheres with prostate cancer cells, the spheres were maintained through serial passaging (Fig. S8A) , and the expression of the stem-cell markers Oct4, Nanog, and Sox2 was increased in spheres compared with adherent cells (Fig. 5A) . When we compared the sphere formation efficiency in cells treated with vehicle or C3, a single dose of C3 on day 0 significantly decreased the number of spheres in LNCaP, abl, and VCaP cells (Fig. 5B and  Fig. S4C ). To test if C3 inhibits sphere-forming abilities of a heterogeneous group of cells obtained from mouse primary prostate cells, we used the mouse model of prostate-specific Pten deletion. In this mouse model, Pten f/f ;PB-Cre, Cre-mediated Pten homozygous deletion is directed by the prostate-specific probasin (PB) promoter (45) . As shown in Fig. S8C , C3 treatment decreased sphere formation efficiency of the primary cells isolated from two Pten f/f ;PB-Cre mice. We also explored the idea that prostate cancer stem cells are resistant to the conventional AR antagonist BIC. LNCaP cells were treated with vehicle, BIC, or C3, and the proliferation of adherent cells as well as the number of spheres in nonadherent culture conditions was determined. Although both 1 and 10 μM BIC showed complete growth inhibition of adherent LNCaP cells (Fig. 5C) , it did not affect sphere formation (Fig. 5D) . However, C3 treatment decreased sphere formation efficiency in a dose-dependent manner (Fig. 5D) , suggesting that sphere-forming cells are resistant to BIC, but susceptible to C3 treatment. In addition, the β-catenin-depleted cell lines phenocopied C3 treatment in sphere assays (Fig. 5E and Fig. S8B ), indicating its requirement for the self-renewal activity needed to form prostate spheres.
C3 Represses Tumor Growth in an in Vivo Xenograft Model of Prostate
Cancer. To determine the effect of C3 on prostate cancer cells in vivo, we used abl cells to generate xenograft tumors. When the tumors reached ∼300 mm 3 , either vehicle or C3 was delivered by intratumor injection. C3 treatment repressed the tumor growth as shown in Fig. 6A . Importantly, the histology of tumors treated with C3 shows dramatic changes in the overall structure, with large empty spaces containing no cells (Fig. 6B, H&E staining) . Immunohistochemistry (IHC) of cleaved caspase 3 and Ki67 in these regions shows more apoptotic cells and fewer proliferating cells compared with vehicle-treated tumors (Fig. 6B) , suggesting that the cell-free areas observed in C3-treated tumors represent necrotic regions. Because AR is a C3 target as well as a master regulator of prostate tumor growth, we also tested the expression level of AR in C3-treated tumors. Consistent with results presented in prostate cancer cell lines (Fig. 2) , the IHC of AR showed a marked decrease in AR expression in C3-treated tumors compared with vehicle-treated tumors (Fig. 6B) .
Discussion
The physical, functional, and genetic interaction of AR and β-catenin has been described in a number of reports (22, 23, 37, 38) . However, targeting this interaction to develop proof-of-concept small-molecule inhibitors as potential therapeutics in prostate cancer has not yet been shown. Here we demonstrate that a smallmolecule inhibitor of the Wnt/β-catenin pathway, C3, can also potently disrupt the AR pathway in prostate cancer by simultaneously disrupting two important protein-protein interactions, TCF/β-catenin and AR/β-catenin. Additionally, disruption of TCF/β-catenin has an additive inhibitory effect on AR signaling by the concomitant down-regulation of AR expression, a transcriptional target of TCF/ β-catenin, thereby exacerbating the effect of C3 on both AR and Wnt/β-catenin signaling activity in prostate cancer. Importantly, C3 inhibits cell growth in a xenograft model of CRPC in vivo, demonstrating proof-of-concept for this therapeutic approach.
Many molecular mechanisms have been suggested to explain the sustained AR signaling in CRPC (5, 46) . In particular, it was suggested that tumor cells adapt to the low androgen environment by activating AR transcriptional activity through alternative signals. In line with this model, the enhanced crosstalk between AR and Wnt/ β-catenin in aggressive disease models has been reported repeatedly (11, 23) . In addition to this "adaptation" mechanism, the other hypothesis is that a small subset of tumor cells becomes resistant to androgen ablation therapy and responsible for recurrent disease (46) . These CSCs are believed to drive tumorigenesis by self-renewal and differentiation (13) . Although the role of Wnt/ β-catenin in embryonic stem-cell self-renewal is controversial (47) , the studies conducted on multiple tumor types have consistently shown that Wnt/β-catenin signaling is highly activated in CSCs (16) (17) (18) , probably due to the effect of the tumor microenvironment. Our data support the idea that prostate CSCs are tolerant to conventional anti-androgen treatment, as the in vitro sphere formation of LNCaP cells was not affected by BIC treatment (Fig.  5D) . However, the sphere-forming efficiency of both LNCaP and abl cells was significantly reduced by C3 treatment (Fig. 5 B and D) , suggesting that the Wnt/β-catenin-signaling pathway can be a good candidate for CSC-targeted drug development.
In conclusion, we show that a small-molecule inhibitor of nuclear β-catenin disrupts both Wnt/β-catenin and AR-signaling activities to induce cell death in prostate cancer cells. Structure and medicinal chemistry-based lead optimization of C3 and scaffold molecules with similar activities may be ideal candidates for Wnt/AR-specific drug development.
Materials and Methods
LNCaP and abl cells were cultured in RPMI 1640 (Cellgro) supplemented with 10% (vol/vol) FBS (HyClone) and 10% (vol/vol) charcoal-stripped FBS (CFBS), respectively, and 1% penicillin-streptomycin (Cellgro). VCaP and HEK293 cells were cultured in Dulbecco's modified Eagle's medium (Cellgro) supplemented with 10% (vol/vol) FBS and 1% penicillin-streptomycin. For quantitative RT-PCR, immunoblot, biochemical fractionation, immunoprecipitation, and ChIP assays, LNCaP and VCaP cells were hormone-deprived in 5% (vol/vol) CFBS media for 3 d and then treated with androgen with or without drug. For xenograft experiments, rapidly cycling abl cells (1.5 × 10 7 ) were mixed with an equal volume of Matrigel and injected s.c. into the flank region of NOD scid gamma (NSG) male mice. When tumors reached an average of 300 mm 3 , mice were randomized into two groups of five and treated by intratumor injection of DMSO or 100 mg/kg C3 (ChemDiv, C523-1410), 5 d a week. Tumor volume was measured twice weekly. All animal studies were performed at the Memorial Sloan-Kettering Cancer Center (MSKCC). The animal research was approved by the MSKCC Institutional Animal Care and Use Committee protocol number 04-03-009. Primer sequences used in this study are provided in Tables S1 and S2 .
Additional methods are available in SI Materials and Methods. 
